EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.

Blood
Eric M J BindelsAshish R Kumar

Abstract

The proto-oncogene EVI1 (ecotropic viral integration site-1), located on chromosome band 3q26, is aberrantly expressed in human acute myeloid leukemia (AML) with 3q26 rearrangements. In the current study, we showed, in a large AML cohort carrying 11q23 translocations, that ∼ 43% of all mixed lineage leukemia (MLL)-rearranged leukemias are EVI1(pos). High EVI1 expression occurs in AMLs expressing the MLL-AF6, -AF9, -AF10, -ENL, or -ELL fusion genes. In addition, we present evidence that EVI1(pos) MLL-rearranged AMLs differ molecularly, morphologically, and immunophenotypically from EVI1(neg) MLL-rearranged leukemias. In mouse bone marrow cells transduced with MLL-AF9, we show that MLL-AF9 fusion protein maintains Evi1 expression on transformation of Evi1(pos) HSCs. MLL-AF9 does not activate Evi1 expression in MLL-AF9-transformed granulocyte macrophage progenitors (GMPs) that were initially Evi1(neg). Moreover, shRNA-mediated knockdown of Evi1 in an Evi1(pos) MLL-AF9 mouse model inhibits leukemia growth both in vitro and in vivo, suggesting that Evi1 provides a growth-promoting signal. Using the Evi1(pos) MLL-AF9 mouse leukemia model, we demonstrate increased sensitivity to chemotherapeutic agents on reduction of Evi1 expression....Continue Reading

References

May 1, 1991·Molecular and Cellular Biology·A S PerkinsN G Copeland
Apr 16, 2004·The New England Journal of Medicine·Lars BullingerJonathan R Pollack
Apr 16, 2004·The New England Journal of Medicine·Peter J M ValkRuud Delwel
Sep 3, 2004·The Journal of Clinical Investigation·Silvia BuonamiciGiuseppina Nucifora
Oct 5, 2007·Blood Cells, Molecules & Diseases·Leopoldo Laricchia-Robbio, Giuseppina Nucifora
Oct 25, 2007·Nature Reviews. Cancer·Andrei V Krivtsov, Scott A Armstrong
Nov 4, 2008·Cancer Cell·Andrei V KrivtsovScott A Armstrong
Dec 26, 2008·Blood·Ashish R KumarJohn H Kersey
Mar 6, 2009·Leukemia·C MeyerR Marschalek
Mar 24, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Stefan GröschelRuud Delwel
Apr 2, 2010·Leukemia·B V BalgobindM M van den Heuvel-Eibrink
Sep 24, 2010·Leukemia·B V BalgobindM M van den Heuvel-Eibrink
Nov 3, 2010·Oncotarget·Jiaying TanJay L Hess
Apr 5, 2011·Genes & Development·Edwin SmithAli Shilatifard
Jul 12, 2011·Cancer Cell·Kathrin M BerntScott A Armstrong
Aug 30, 2011·Nature Medicine·Kolja EppertJohn E Dick

❮ Previous
Next ❯

Citations

Mar 22, 2013·Leukemia·J de BoerO Williams
Jul 5, 2013·PloS One·Carolyn GlassArchibald Perkins
Feb 25, 2014·International Journal of Hematologic Oncology·Andrew G Muntean
Oct 27, 2015·International Journal of Oncology·Xiaofen YuanGuosheng Jiang
Dec 1, 2013·Surgical Pathology Clinics·Heesun J Rogers, Eric D Hsi
Jan 6, 2016·British Journal of Haematology·Adil A Hinai, Peter J M Valk
Feb 6, 2014·Blood Cells, Molecules & Diseases·Carolyn GlassArchibald S Perkins
Apr 18, 2015·Journal of Hematology & Oncology·Gerwin HellerRotraud Wieser
Sep 12, 2013·Blood·Yi ZhangArchibald S Perkins
Jan 26, 2017·Journal of Pediatric Hematology/oncology·Yueli RaoJie Yan
Jan 24, 2019·International Journal of Molecular Sciences·Marwa Almosailleakh, Juerg Schwaller
Feb 25, 2017·Frontiers in Pediatrics·Amanda C Winters, Kathrin M Bernt
Jan 25, 2019·Scientific Reports·Akira SuekaneKazuhiro Morishita
Sep 27, 2018·Molecular & Cellular Oncology·Vaia StavropoulouJuerg Schwaller
May 20, 2020·Indian Journal of Hematology & Blood Transfusion : an Official Journal of Indian Society of Hematology and Blood Transfusion·Irena MarjanovicNatasa Tosic
Nov 15, 2019·HemaSphere·James Neil FisherJuerg Schwaller
Jul 2, 2020·Cancer Discovery·Sheng F CaiScott A Armstrong
Mar 24, 2021·Blood Cancer Journal·Christine BirdwellKapil N Bhalla
Jul 3, 2021·Genes·Julie QuessadaMarina Lafage-Pochitaloff

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.